

# PET $CMR_{glc}$ mapping and $^1H$ MRS show altered glucose uptake and neurometabolic profiles in a rat model of type C hepatic encephalopathy

J. Mosso<sup>1,2,3</sup>, T. Yin<sup>1,2</sup>, C. Poitry-Yamate<sup>1</sup>, D. Simicic<sup>1,2</sup>, M. Lepore<sup>1,2</sup>, V. A. McLin<sup>4</sup>, O. Braissant<sup>5</sup>, C. Cudalbu<sup>1,2</sup>, B. Lanz<sup>1,2</sup>

1 CIBM Center for Biomedical Imaging, Switzerland, 2 Animal Imaging and Technology (AIT), EPFL, Lausanne, Switzerland, 3 Laboratory for Functional and Metabolic Imaging (LIFMET), EPFL, Lausanne, Switzerland, 4 Swiss Pediatric Liver Center, Department of Pediatrics, Gynecology and Obstetrics, University Hospitals Geneva, And University of Geneva, Geneva, Switzerland, 5 Service of Clinical Chemistry, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

## INTRODUCTION

- Type C hepatic encephalopathy (HE): severe neuropsychiatric decline following chronic liver disease
- Poor ammonia detoxification by the liver → toxin accumulation in the brain and a cascade of metabolic alterations<sup>1-4</sup>


## AIMS

- A-** Investigate brain energy metabolism in a rat model of type C HE using PET and MR spectroscopy (MRS)
- B-** Implement quantitative glucose cerebral metabolic rate ( $CMR_{glc}$ ) map with an image-derived input function for minimal invasiveness and register the PET image to an atlas for ROI-based analysis

## METHODS

- Bile duct-ligated (BDL) male Wistar rats, model of type C HE
- $^1H$  MRS: 9.4 T Varian scanner, SPECIAL<sup>5</sup> sequence (TE=2.8ms), 2 brain regions (voxel sizes – cerebellum: 2.5<sup>3</sup> mm<sup>3</sup>, hippocampus: 2.8x2x2 mm<sup>3</sup>), 2 time points: week 0 as control (n∈{3,4}) and 6 post-surgery (n∈{4,9})
- $^{18}F$ -FDG PET: Avalanche photodiode LabPET 4 scanner
- (1)-Image derived input function (IDIF): 45min dynamic acquisition on the vena cava<sup>6</sup>
- (2)-Quantitative 3D brain maps: 15min static acquisition on the brain (nominal resolution: 0.5x0.5x1.18 mm<sup>3</sup>)
- $CMR_{glc}$ <sup>7</sup> maps with LC 0.71<sup>8</sup>, PET-atlas registration, 1 time point: week 6 post surgery (n<sub>SHAM</sub>=8, n<sub>BDL</sub>=10)

## DISCUSSION



Issues with the standardized uptake value (SUV):


- The dose does not reflect the tracer availability for the brain when systemic effects occur, but the IF does
- The weight does not inform on Glc/FDG competitive uptake and glycemia is not taken into account

## CONCLUSIONS

**Pathophysiology in a rat model of type C HE:** increased brain glutamine and decreased osmolytes in the cerebellum and the hippocampus measured by  $^1H$  MRS, 2-fold lower glucose cerebral metabolic rate measured by  $^{18}F$ -FDG PET


**Methodology:** minimally invasive, quantitative and spatial mapping of  $CMR_{glc}$  using an image-derived IF and an atlas registration, limitations of the SUV when systemic metabolic effects occur

## RESULTS - PET



- IDIF (1) performs as well as manual blood samplings and external blood counters, is non-invasive, and allows for longitudinal studies
- 2-fold lower  $CMR_{glc}$  in BDL rats
- energy metabolism alterations in BDL rats

## RESULTS - MRS



In BDL rats:

- Increase in Gln (stronger in the cerebellum)
- Decrease in Glu, sum of osmolytes (Ins, Tau, tCr, tCho)
- Alterations in diverse brain functions: Gln metabolism and osmoregulation, neurotransmission, energy metabolism